RxDoctor Payments Data

Heenaben Rathod

Nurse Practitioner · Houston, TXNPI 1417566548

Payments from drug & device makers

$2,095in general payments, 2019–2025

Across 108 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$458
  • Novo Nordisk$415
  • AstraZeneca$248
  • Otsuka America Pharmaceutical, Inc.$212
  • Exact Sciences$196
  • Lilly USA, LLC$160
  • plus $407 from 12 others

What the payments were for

  • Food & beverage$2,095100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,095 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$25,213
Medicare patients
109
Services billed
538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$97,981
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$57,521
FarxigaDapagliflozin Propanediol50$53,631
BiktarvyBictegrav/Emtricit/Tenofov Ala13$51,686
JardianceEmpagliflozin28$44,953
RybelsusSemaglutide26$44,912
TrulicityDulaglutide15$23,192
EliquisApixaban17$21,690
XareltoRivaroxaban12$15,564
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$13,698
JanuviaSitagliptin Phosphate11$12,044
Tresiba Flextouch U-200Insulin Degludec12$10,931
ShingrixVaricella-Zoster Ge/As01b/Pf39$8,461
Levemir FlexpenInsulin Detemir19$4,021
Gabapentin244$3,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$415$142,89385 claims
AstraZenecaFarxiga, Breztri Aerosphere$248$67,32867 claims
GSKTrelegy Ellipta, Shingrix$458$65,98296 claims
Boehringer IngelheimJardiance$45$44,95328 claims
Lilly USA, LLCTrulicity$160$23,19215 claims
PfizerEliquis, Paxlovid$38$23,04932 claims
Johnson & JohnsonXarelto$17$15,56412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →